COVID-19 Therapeutics: An Update on Effective Treatments Against Infection With SARS-CoV-2 Variants

키워드

참고문헌 (155)

1. "WHO coronavirus (COVID-19) dashboard"[URL]
2. "WHO Director-General’s opening remarks at the media briefing on COVID-19" (2020)[URL]
3. Lu R, "Genomic characterisation and epidemiology of 2019 novel coronavirus : implications for virus origins and receptor binding", Lancet, 395, pp.565~574 (2020)
4. Chan JF, "Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan", Emerg Microbes Infect, 9, pp.221~236 (2020)
5. Du L, "The spike protein of SARS-CoV--a target for vaccine and therapeutic development", Nat Rev Microbiol, 7, pp.226~236 (2009)
6. Hamming I, "Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis", J Pathol, 203, pp.631~637 (2004)
7. Li W, "Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus", Nature, 426, pp.450~454 (2003)
8. Jackson CB, "Mechanisms of SARS-CoV-2 entry into cells", Nat Rev Mol Cell Biol, 23, pp.3~20 (2022)
9. Abulsoud AI, "Mutations in SARS-CoV-2 : insights on structure, variants, vaccines, and biomedical interventions", Biomed Pharmacother, 157, pp.113977~ (2023)
10. V’kovski P, "Coronavirus biology and replication : implications for SARS-CoV-2", Nat Rev Microbiol, 19, pp.155~170 (2021)
11. Snijder EJ, "The nonstructural proteins directing coronavirus RNA synthesis and processing", Adv Virus Res, 96, pp.59~126 (2016)
12. Anand K, "Coronavirus main proteinase(3CLpro)structure : basis for design of anti-SARS drugs", Science, 300, pp.1763~1767 (2003)
13. Aftab SO, "Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach", J Transl Med, 18, pp.275~ (2020)
14. Chen J, "Mutations strengthened SARS-CoV-2 infectivity", J Mol Biol, 432, pp.5212~5226 (2020)
15. Harvey WT, "COVID-19 Genomics UK(COG-UK)Consortium SARS-CoV-2 variants, spike mutations and immune escape", Nat Rev Microbiol, 19, pp.409~424 (2021)
16. Kim Sinae, "SARS-CoV-2 Omicron Mutation Is Faster than the Chase: Multiple Mutations on Spike", ACE2 Interaction Residues, 2021, pp.21(6), 1~8[DOI]
17. "Tracking SARS-CoV-2 variants"[URL]
18. Tegally H, "Sixteen novel lineages of SARS-CoV-2 in South Africa", Nat Med, 27, pp.440~446 (2021)
19. Eastman RT, "Remdesivir : a review of its discovery and development leading to emergency use authorization for treatment of COVID-19", ACS Cent Sci, 6, pp.672~683 (2020)
20. Gordon CJ, "Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency", J Biol Chem, 295, pp.6785~6797 (2020)
21. Sheahan TP, "Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses", Sci Transl Med, 9 (2017)
22. Wang M, "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV)in vitro", Cell Res, 30, pp.269~271 (2020)
23. Pruijssers AJ, "Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice", Cell Reports, 32, pp.107940~ (2020)
24. Choy KT, "Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro", Antiviral Res, 178, pp.104786~ (2020)
25. Williamson BN, "Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2", Nature, 585, pp.273~276 (2020)
26. de Wit E, "Prophylactic and therapeutic remdesivir(GS-5734)treatment in the rhesus macaque model of MERS-CoV infection", Proc Natl Acad Sci U S A, 117, pp.6771~6776 (2020)
27. Beigel JH, "Remdesivir for the treatment of Covid-19-final report", N Engl J Med, 383, pp.1813~1826 (2020)
28. Goldman JD, "Remdesivir for 5 or 10 days in patients with severe Covid-19", N Engl J Med, 383, pp.1827~1837 (2020)
29. Spinner CD, "Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19 : a randomized clinical trial", JAMA, 324, pp.1048~1057 (2020)
30. Day RO, "Open-label extension studies : do they provide meaningful information on the safety of new drugs?", Drug Saf, 30, pp.93~105 (2007)
31. WHO Solidarity Trial Consortium, "Remdesivir and three other drugs for hospitalised patients with COVID-19 : final results of the WHO Solidarity randomised trial and updated meta-analyses", Lancet, 399, pp.1941~1953 (2022)
32. Gottlieb RL, "Early remdesivir to prevent progression to severe Covid-19 in outpatients", N Engl J Med, 386, pp.305~315 (2022)
33. Solera JT, "Short-course early outpatient remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the Omicron BA. 2 wave", Am J Transplant, 23, pp.78~83 (2023)
34. Takashita E, "Efficacy of antibodies and antiviral drugs against Omicron BA. 2. 12. 1, BA. 4, and BA. 5 subvariants", N Engl J Med, 387, pp.468~470 (2022)
35. Imai M, "Efficacy of antiviral agents against omicron subvariants BQ. 1. 1 and XBB", N Engl J Med, 388, pp.89~91 (2023)
36. "FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness"[URL]
37. "Veklury"[URL]
38. Huang P., "Why remdesivir, a highly effective COVID treatment, is a last resort for providers", NPR, ~ (2022)
39. Toots M, "Next-generation direct-acting influenza therapeutics", Transl Res, 220, pp.33~42 (2020)
40. Painter GR, "The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection", Antiviral Res, 171, pp.104597~ (2019)
41. Yoon JJ, "Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses", Antimicrob Agents Chemother, 62, pp.e00766~ (2018)
42. Gordon CJ, "Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template", J Biol Chem, 297, pp.100770~ (2021)
43. Toots M, "Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia", Sci Transl Med, 11 (2019)
44. Agostini ML, "Small-molecule antiviral β-d-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance", J Virol, 93 (2019)
45. Barnard DL, "Inhibition of severe acute respiratory syndrome-associated coronavirus(SARSCoV)by calpain inhibitors and β-D-N4-hydroxycytidine", Antivir Chem Chemother, 15, pp.15~22 (2004)
46. Ehteshami M, "Characterization of β-d-N4-hydroxycytidine as a novel inhibitor of chikungunya virus", Antimicrob Agents Chemother, 61 (2017)
47. Reynard O, "Identification of a new ribonucleoside inhibitor of Ebola virus replication", Viruses, 7, pp.6233~6240 (2015)
48. Stuyver LJ, "Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture", Antimicrob Agents Chemother, 47, pp.244~254 (2003)
49. Urakova N, "β-d-N4-hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome", J Virol, 92 (2018)
50. Zhao J, "A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase", Antiviral Res, 190, pp.105078~ (2021)
51. Cox RM, "Therapeutically administered ribonucleoside analogue MK-4482", EIDD-2801 blocks SARS-CoV-2 transmission in ferrets, 2021, pp.6, 11~18
52. Abdelnabi R, "Molnupiravir inhibits replication of the emerging SARS-CoV-2 variants of concern in a hamster infection model", J Infect Dis, 224, pp.749~753 (2021)
53. Painter WP, "Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2", Antimicrob Agents Chemother, 65 (2021)
54. Fischer WA 2nd, "A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus", Sci Transl Med, 14 (2022)
55. Jayk Bernal A, "Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients", N Engl J Med, 386, pp.509~520 (2022)
56. "EMA issues advice on use of Lagevrio (molnupiravir) for the treatment COVID-19"[URL]
57. "WHO updates its treatment guidelines to include molnupiravir"[URL]
58. "Coronavirus (COVID-19) update: FDA authorizes additional oral antiviral for treatment of COVID-19 in certain adults"[URL]
59. Wong CK, "Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong : an observational study", Lancet, 400, pp.1213~1222 (2022)
60. Hoffman RL, "Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19", J Med Chem, 63, pp.12725~12747 (2020)
61. Jin Z, "Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors", Nature, 582, pp.289~293 (2020)
62. Ullrich S, "The SARS-CoV-2 main protease as drug target", Bioorg Med Chem Lett, 30, pp.127377~ (2020)
63. Boras B, "Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19", Nat Commun, 12, pp.6055~ (2021)
64. Owen DR, "An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19", Science, 374, pp.1586~1593 (2021)
65. Lamb YN, "Nirmatrelvir plus ritonavir : first approval", Drugs, 82, pp.585~591 (2022)
66. Reis S, "Nirmatrelvir combined with ritonavir for preventing and treating COVID-19", Cochrane Database Syst Rev, 9, pp.CD015395~ (2022)
67. "Pfizer’s novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study"[URL]
68. Hammond J, "Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19", N Engl J Med, 386, pp.1397~1408 (2022)
69. Gentile I, "Nirmatrelvir", ritonavir and molnupiravir in the treatment of mild, Vaccines(Basel), pp.2022, 10[DOI]
70. "Nirmatrelvir and the risk of post-acute sequelae of COVID-19" (2022)[URL]
71. Cao Z, "VV116 versus nirmatrelvir-ritonavir for oral treatment of Covid-19", N Engl J Med, 388, pp.406~417 (2023)
72. "Paxlovid"[URL]
73. "COVID-19 antiviral, Paxlovid, approved by UK regulator"[URL]
74. "Pfizer receives health canada authorization for COVID-19 oral treatment"[URL]
75. "TGA provisionally approves two oral COVID-19 treatments, molnupiravir (LAGEVRIO) and nirmatrelvir + ritonavir (PAXLOVID)"[URL]
76. "PAXLOVID™"[URL]
77. Keating GM, "Sofosbuvir : first global approval", Drugs, 74, pp.273~282 (2014)
78. Xu HT, "Evaluation of sofosbuvir(β-D-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine)as an inhibitor of Dengue virus replication", Sci Rep, 7, pp.6345~ (2017)
79. Bullard-Feibelman KM, "The FDA-approved drug sofosbuvir inhibits Zika virus infection", Antiviral Res, 137, pp.134~140 (2017)
80. Ferreira AC, "Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication", Antimicrob Agents Chemother, 63 (2019)
81. Ju J, "Nucleotide analogues as inhibitors of SARS-CoV polymerase", Pharmacol Res Perspect, 8, pp.e00674~ (2020)
82. Elfiky AA, "SARS-CoV-2 RNA dependent RNA polymerase(RdRp)targeting : an in silico perspective", J Biomol Struct Dyn, 39, pp.3204~3212 (2021)
83. Jockusch S, "Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir", Sci Rep, 10, pp.16577~ (2020)
84. Messina V, "Efficacy and safety of the sofosbuvir", velpatasvir combination for the treatment of patients with early mild to moderate COVID-19, 2022, pp.12, 5771~
85. Sayad B, "Efficacy and safety of sofosbuvir", velpatasvir versus the standard of care in adults hospitalized with COVID-19 : a single-centre, randomized controlled trial, 2021, pp.76, 2158~2167
86. Roozbeh F, "Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients : a double-blind, randomized controlled trial", J Antimicrob Chemother, 76, pp.753~757 (2021)
87. Españo Erica, "COVID-19 Antiviral and Treatment Candidates: Current Status", Immune Network, 21(1), pp.1~24 (2021), 대한면역학회[DOI]
88. Sokhela S, "Randomized clinical trial of nitazoxanide or sofosbuvir", daclatasvir for the prevention of SARS-CoV-2 infection, 2022, pp.77, 2706~2712
89. Tobback E, "Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting : a randomized placebo-controlled phase II trial", Int J Infect Dis, 122, pp.628~635 (2022)
90. Hoffmann M, "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor", Cell, 181, pp.271~280 (2020)
91. Zhou Y, "Protease inhibitors targeting coronavirus and filovirus entry", Antiviral Res, 116, pp.76~84 (2015)
92. Sakr Y, "Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia", Intensive Care Med, 47, pp.707~709 (2021)
93. Gunst JD, "Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial", EClinicalMedicine, 35, pp.100849~ (2021)
94. "A phase 2 randomized, double-blind, placebo-controlled trial of oral camostat mesylate for early treatment of COVID-19 outpatients showed shorter illness course and attenuation of loss of smell and taste" (2022)[URL]
95. Yamamoto M, "The anticoagulant nafamostat potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-type-dependent manner", Viruses, 12, pp.629~ (2020)
96. Hoffmann M, "Nafamostat mesylate blocks activation of SARS-CoV-2 : new treatment option for COVID-19", Antimicrob Agents Chemother, 64, pp.e00754~ (2020)
97. Quinn TM, "Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis : Phase 1b", 2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics, 2022, pp.76, 103856~
98. Zhuravel SV, "Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia : a randomised Phase II clinical trial", EClinicalMedicine, 41, pp.101169~ (2021)
99. "LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants" (2022)[URL]
100. "Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19" (2022)[URL]
101. "Coronavirus (COVID-19) update: FDA authorizes new monoclonal antibody for treatment of COVID-19 that retains activity against omicron variant"[URL]
102. Dryden-Peterson S, "Bebtelovimab for high-risk outpatients with early COVID-19 in a large US health system", Open Forum Infect Dis, 9 (2022)
103. "FDA updates on bebtelovimab"[URL]
104. "Announces bebtelovimab is not currently authorized in any US region"[URL]
105. Levin MJ, "Intramuscular AZD7442(tixagevimab-cilgavimab)for prevention of Covid-19", N Engl J Med, 386, pp.2188~2200 (2022)
106. Loo YM, "The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans", Sci Transl Med, 14 (2022)
107. Dong J, "Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail", Nat Microbiol, 6, pp.1233~1244 (2021)
108. "AZD7442 PROVENT phase III prophylaxis trial met primary endpoint in preventing COVID-19"[URL]
109. "FDA releases important information about risk of COVID-19 due to certain variants not neutralized by evusheld" (2022)[URL]
110. VanBlargan LA, "An infectious SARS-CoV-2 B. 1. 1. 529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies", Nat Med, 28, pp.490~495 (2022)
111. "FDA announces Evusheld is not currently authorized for emergency use in the U.S"[URL]
112. Hurt AC, "Neutralizing antibody therapeutics for COVID-19", Viruses, 13, pp.628~ (2021)
113. Nathan R, "A narrative review of the clinical practicalities of bamlanivimab and etesevimab antibody therapies for SARS-CoV-2", Infect Dis Ther, 10, pp.1933~1947 (2021)
114. Dougan M, "Bamlanivimab plus etesevimab in mild or moderate Covid-19", N Engl J Med, 385, pp.1382~1392 (2021)
115. Deeks ED, "Casirivimab", imdevimab : first approval, 2021, pp.81, 2047~2055
116. Razonable RR, "Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19", EClinicalMedicine, 40, pp.101102~ (2021)
117. Weinreich DM, "REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19", N Engl J Med, 384, pp.238~251 (2021)
118. RECOVERY Collaborative Group, "Casirivimab and imdevimab in patients admitted to hospital with COVID-19(RECOVERY) : a randomised, controlled, open-label, platform trial", Lancet, 399, pp.665~676 (2022)
119. "Coronavirus (COVID-19) update: FDA limits use of certain monoclonal antibodies to treat COVID-19 due to the Omicron variant"[URL]
120. Kim C, "A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein", Nat Commun, 12, pp.288~ (2021)
121. Kim JY, "A randomized clinical trial of regdanvimab in high-risk patients with mild-to-moderate coronavirus disease 2019", Open Forum Infect Dis, 9 (2022)
122. "Regkirona"[URL]
123. Li M, "SARS-CoV-2 variant Omicron : currently the most complete"escapee"from neutralization by antibodies and vaccines", Signal Transduct Target Ther, 7, pp.28~ (2022)
124. Heo YA, "Sotrovimab : First Approval", Drugs, 82, pp.477~484 (2022)
125. Gupta A, "Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab", N Engl J Med, 385, pp.1941~1950 (2021)
126. "FDA updates sotrovimab emergency use authorization"[URL]
127. Fu B, "Why tocilizumab could be an effective treatment for severe COVID-19?", J Transl Med, 18, pp.164~ (2020)
128. Rubin EJ, "Interleukin-6 receptor inhibition in Covid-19-cooling the inflammatory soup", N Engl J Med, 384, pp.1564~1565 (2021)
129. 강연우, "Understanding the Host Innate Immune Responses against SARS-CoV-2 Infection and COVID-19 Pathogenesis", Immune Network, 21(1), pp.1~16 (2021), 대한면역학회[DOI]
130. Channappanavar R, "Pathogenic human coronavirus infections : causes and consequences of cytokine storm and immunopathology", Semin Immunopathol, 39, pp.529~539 (2017)
131. Moore JB, "Cytokine release syndrome in severe COVID-19", Science, 368, pp.473~474 (2020)
132. Chen G, "Clinical and immunological features of severe and moderate coronavirus disease 2019", J Clin Invest, 130, pp.2620~2629 (2020)
133. REMAP-CAP Investigators, "Interleukin-6 receptor antagonists in critically ill patients with Covid-19", N Engl J Med, 384, pp.1491~1502 (2021)
134. RECOVERY Collaborative Group, "Tocilizumab in patients admitted to hospital with COVID-19(RECOVERY) : a randomised, controlled, open-label, platform trial", Lancet, 397, pp.1637~1645 (2021)
135. Rosas IO, "Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia : a randomized clinical trial", Intensive Care Med, 47, pp.1258~1270 (2021)
136. "FDA roundup" (2022)[URL]
137. Sönmez HE, "Anakinra treatment in macrophage activation syndrome : a single center experience and systemic review of literature", Clin Rheumatol, 37, pp.3329~3335 (2018)
138. Monteagudo LA, "Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome", ACR Open Rheumatol, 2, pp.276~282 (2020)
139. Cavalli G, "Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation : a retrospective cohort study", Lancet Rheumatol, 2, pp.e325~e331 (2020)
140. Huet T, "Anakinra for severe forms of COVID-19 : a cohort study", Lancet Rheumatol, 2, pp.e393~e400 (2020)
141. Kyriazopoulou E, "Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels : a double-blind, randomized controlled phase 3 trial", Nat Med, 27, pp.1752~1760 (2021)
142. "Emergency use authorization"[URL]
143. Stebbing J, "COVID-19 : combining antiviral and anti-inflammatory treatments", Lancet Infect Dis, 20, pp.400~402 (2020)
144. Richardson P, "Baricitinib as potential treatment for 2019-nCoV acute respiratory disease", Lancet, 395, pp.e30~e31 (2020)
145. Stebbing J, "Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients", EMBO Mol Med, 12, pp.e12697~ (2020)
146. Zhou F, "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study", Lancet, 395, pp.1054~1062 (2020)
147. Huang KJ, "An interferon-γ-related cytokine storm in SARS patients", J Med Virol, 75, pp.185~194 (2005)
148. Kalil AC, "Baricitinib plus remdesivir for hospitalized adults with Covid-19", N Engl J Med, 384, pp.795~807 (2021)
149. "FDA approves Lilly and Incyte’s OLUMIANT® (baricitinib) for the treatment of certain hospitalized patients with COVID-19 | Eli Lilly and Company"[URL]
150. Russell CD, "Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury", Lancet, 395, pp.473~475 (2020)
151. Nhean S, "COVID-19: a review of potential treatments (corticosteroids, remdesivir, tocilizumab, bamlanivimab", etesevimab, and casirivimab, J Pharm Pract, pp.2021[DOI]
152. Hafkamp Florianne M.J., "Dexamethasone, but Not Vitamin D or A, Dampens the Inflammatory Neutrophil Response to Protect At-risk COVID-19 Patients", Immune Network, 22(4), pp.1~12 (2022), 대한면역학회[DOI]
153. "Dexamethasone in hospitalized patients with Covid-19 — preliminary report", N Engl J Med, 384, pp.693~704 (2020)
154. "EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation"[URL]
155. "Corticosteroids"[URL]

관련 논문AI추천